Brief India: Glenmark Pharmaceutical Ltd ~ Ambitious Guidance or Realistic Roadmap? and more
In this briefing: Glenmark Pharmaceutical Ltd ~ Ambitious Guidance or Realistic Roadmap? Exencial Industry Tidings 30/12/2025 Stylam Industries: Promoter Sell-Off: Clearing Family Dispute Cloud. Upgrade to ADD Max Healthcare Institute: Steady Growth Visbility, Margin Hinges on Execution. Pick of the Week: Skipper Limited - 27th December, 2025 1. Glenmark Pharmaceutical Ltd ~ Ambitious Guidance or Realistic Roadmap? Glenmark Pharmaceuticals (GNP IN) is executing a strategic "3.0" transformation into a science-led innovator , following a landmark $1.925 billion AbbVie partnership. Q2 India sales fell 87% due to GST-related distributor inventory rationalization, with normalized revenue recovery of INR 1,150–1,200 crore expected from Q3. Management targets 15% annual revenue growth and 25% EBITDA margins by FY27, supported by a zero-gross-debt balance sheet . 2. Exencial Industry Tidings 30/12/2025 Madhya Pradesh govt attracts investment proposals worth Rs.27.8 bln in 1 month Beer & other undistilled liquor production falls by 2.6% in November 2025 Sweetmeat & sugar confectionary production up 19.9% in November 2025 3.